Myocardial Infarction News and Research

RSS

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

Medtronic commences clinical evaluation of CoreValve transcatheter aortic valve system

Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic, Inc., today announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic valve replacement.

15 Mar 2010

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's LipiScan™ Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology.

11 Mar 2010

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Atherotech Inc. today announced it will be presenting research in two poster sessions and exhibiting its VAP® Cholesterol Test in booth #1311 at the American College of Cardiology (ACC) 59th Annual Scientific Session Exposition. The annual meeting takes place March 14-16, 2010, at the Georgia World Congress Center in Atlanta.

9 Mar 2010

Stentys receives CE Marking for its self-expanding and disconnectable stent

Medical device pioneer Stentys announced today that it has received CE Marking for its self-expanding and disconnectable stent to treat acute coronary syndrome (ACS).

5 Mar 2010

Isotechnika Pharma receives grant of $237,069 to support NICAM program

Isotechnika Pharma Inc. today announced that it has received funding approval from the National Research Council's Industrial Research Assistance Program (IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program.

5 Mar 2010

RMR can non-invasively, quickly and accurately detect presence of sCAD

Newly published data shows using a Respiratory Modulation Response (RMR) is a novel, non-invasive measure to quickly and accurately detect the presence of significant coronary artery disease (sCAD). Patients in the study with sCAD had a lower RMR compared to patients without, regardless of their risk factors or clinical history of angina, previous myocardial infarction (MI), or angioplasty.

3 Mar 2010

MRG: Preliminary results from CREST will increase growth in carotid stenting procedures

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, recent preliminary results from the CREST (Carotid Revascularization Endarterectomy versus Stenting Trial) will support growth in carotid stenting procedures of more than 10% over the next five years. The results were announced last week at the American Stroke Association International Stroke Conference 2010.

3 Mar 2010

French investigation explores the outcome of physical functioning of coronary angioplasty

A French investigation published in the current issue of Psychotherapy and Psychosomatics has explored the outcome in terms of physical functioning of coronary angioplasty.

2 Mar 2010

FiberNet EPS has 97.5% success rate in patients undergoing CAS: EPIC study

A multicenter EPIC (FiberNet- Embolic Protection System in Carotid Artery Stenting Trial) study found that the FiberNet Embolic Protection System (EPS) had a 97.5% success rate when used in patients undergoing carotid artery stenting (CAS). Full findings are published early online in Catheterization and Cardiovascular Interventions, the official journal of The Society for Cardiovascular Angiography and Interventions.

1 Mar 2010

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

For dialysis patients, high scores on a new fatigue rating scale predict an increased risk of heart attack or other cardiovascular events, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

InfraReDx to exhibit novel LipiScan Coronary Imaging System at LUMEN 2010

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention.

24 Feb 2010

PressureWire Aeris technology now available to hospitals using Horizon Cardiology Hemo solution

St. Jude Medical, Inc. announced today its wireless PressureWire™ Aeris technology, which aids in the diagnosis and treatment of coronary artery blockages by measuring Fractional Flow Reserve (FFR), will now be available to hospitals using the McKesson Horizon Cardiology Hemo™ solution.

24 Feb 2010

New treatments for heart disease

Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases. The first study, carried out by a team of Brazilian researchers, found that cell transplantation of bone marrow mononuclear cells (BMMCs) directly into the heart benefited patients suffering from refractory angina.

24 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

AHA Scientific Statement: Only 33% of annual PCIs are performed in women

President Clinton’s stent surgery brought new focus to America’s number-one killer, but it did little to expose the bias that is often present when women seek treatment for a heart attack.

18 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT

OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.

15 Feb 2010

Anti-PC antibody linked to reduced risk of arteriosclerosis

The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The researchers hope to be able to develop a vaccine that can mobilise the body's own defence against arteriosclerosis and stroke.

12 Feb 2010

Myocardial Infarction News and Research

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

Medtronic commences clinical evaluation of CoreValve transcatheter aortic valve system

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Stentys receives CE Marking for its self-expanding and disconnectable stent

Isotechnika Pharma receives grant of $237,069 to support NICAM program

RMR can non-invasively, quickly and accurately detect presence of sCAD

MRG: Preliminary results from CREST will increase growth in carotid stenting procedures

French investigation explores the outcome of physical functioning of coronary angioplasty

FiberNet EPS has 97.5% success rate in patients undergoing CAS: EPIC study

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

Study demonstrates Prochymal treamtent is safe for cardiac patients

InfraReDx to exhibit novel LipiScan Coronary Imaging System at LUMEN 2010

PressureWire Aeris technology now available to hospitals using Horizon Cardiology Hemo solution

New treatments for heart disease

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

AHA Scientific Statement: Only 33% of annual PCIs are performed in women

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT

Anti-PC antibody linked to reduced risk of arteriosclerosis

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News